Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Organisation › Details

Avilex Pharma ApS

Avilex Pharma is a Danish biotech company with technology developed at the Department of Drug Design and Pharmacology of the University of Copenhagen. Through the use of innovative dimeric ligands we can target well established intracellular targets with unprecedented potency with the aim of developing novel medicines for a range of areas of unmet medical need. *


Period Start 2013-04-15 splitoff (date ca.)
  Predecessor University of Copenhagen
Product Industry drug development
Persons Person Tansley, Robert (Cambridge Innovation Capital 201401– Investment Director before KalVista + Avilex Pharma)
  Person 2 Strømgaard, Kristian (Univ Copenhagen 201304 Prof Avilex Pharma ApS –201304– CSO + Co-founder)
Region Region København (Copenhagen)
  Country Denmark
  Street 3 Ole Maaløes Vej
  City 2200 København
  Tel +45-3527-6599
    Address record changed: 2016-04-09
Basic data Employees n. a.
    * Document for �About Section�: Avilex Pharma ApS. (4/15/13). "Press Release: Avilex Pharma, a Spin Out Company from the University of Copenhagen, Announces Seed Investment from Novo Seeds". Copenhagen.
Record changed: 2017-04-01


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Avilex Pharma ApS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top